Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist

BACKGROUND: In contrast to immune checkpoint inhibitors, the use of antibodies as agonists of immune costimulatory receptors as cancer therapeutics has largely failed. We sought to address this problem using a new class of modular synthetic drugs, termed tumor-targeted immune cell agonists (TICAs),...

Descripción completa

Detalles Bibliográficos
Autores principales: Upadhyaya, Punit, Lahdenranta, Johanna, Hurov, Kristen, Battula, Sailaja, Dods, Rachel, Haines, Eric, Kleyman, Marianna, Kristensson, Julia, Kublin, Jessica, Lani, Rachid, Ma, Jun, Mudd, Gemma, Repash, Elizabeth, Van Rietschoten, Katerine, Stephen, Tom, You, Fanglei, Harrison, Helen, Chen, Liuhong, McDonnell, Kevin, Brandish, Philip, Keen, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839861/
https://www.ncbi.nlm.nih.gov/pubmed/33500260
http://dx.doi.org/10.1136/jitc-2020-001762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839861/
https://www.ncbi.nlm.nih.gov/pubmed/33500260
http://dx.doi.org/10.1136/jitc-2020-001762

Ejemplares similares